<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report: January 19, 1998
(Date of earliest event reported)
LIDAK PHARMACEUTICALS
(Exact name of registrant as specified in its charter)
CALIFORNIA
(State or other jurisdiction of incorporation)
0-18734 33-0314804
(Commission File Number) (IRS Employer Identification No.)
11077 North Torrey Pines Road, La Jolla, California 92037
(Address of principal executive offices) (Zip code)
(619) 558-0364
(Registrants telephone number, including area code)
<PAGE> 2
Item 5. OTHER EVENTS
The registrant incorporates by reference herein the press release dated
January 19, 1998, attached hereto as Exhibit 99.
Item 7. Financial Statements and Exhibits
(c) Exhibits
(i) Exhibit 99 -- Press Release dated January 19, 1998.
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
LIDAK PHARMACEUTICALS
Date: January 21, 1998 By: \s\Jeffery B. Weinress
--------------------------------
Jeffery B. Weinress
Vice President and Chief Financial
Officer
<PAGE> 1
EXHIBIT 99
DATE: January 19, 1998 CONTACT: Jeffery B. Weinress
Vice President/CFO
RELEASE DATE: IMMEDIATE LIDAK Pharmaceuticals
(619) 558-0364, ext. 242
LIDAK PHARMACEUTICALS
NEWS RELEASE
LIDAK PHARMACEUTICALS ANNOUNCES CHANGE IN BOARD CHAIRMANSHIP
LA JOLLA, CALIFORNIA -- January 19, 1998 -- LIDAK Pharmaceuticals
(NASDAQ NM: LDAKA) announced that on January 12, 1998, Daniel J. Paracka
resigned as chairman of the board and a director of the Company. His resignation
came after presiding over LIDAK's final Board meeting of the year before the
next scheduled Annual Shareholders' Meeting in early Spring. Mr. Paracka had
previously announced his intentions to make this his last year of service during
a gathering of board members last November.
On January 13, 1998, the remaining Board members appointed William N.
Jenkins to serve as Chairman of the Board.
Commenting on these changes, Dr. David H. Katz, LIDAK's president and
CEO, said "Dan Paracka has been a major contributor to the growth of this
Company since joining the board in early 1992. I know that i reflect the
sentiments of all of my fellow directors that he will be sorely missed. Mr.
Jenkins, as a founding director of LIDAK, is a fitting replacement for Dan and
recognizes that he will be challenged to fill Dan's large shoes."
LIDAK Pharmaceuticals is developing therapeutic products against
virally caused diseases, allergies and asthma, inflammatory disorders and
cancer.
# # #
The information contained in this press release, including any forward looking
statements contained herein, should be reviewed in conjunction with the
Company's Annual Report on Form 10-K and other publicly available information
regarding the Company, copies of which are available from the Company upon
request. Such publicly available information sets forth many risks and
uncertainties related to the Company's business and such statements, including
risks and uncertainties related to drug development and clinical trials. Final
review decisions made by the FDA and other regulatory agencies concerning
clinical trial results are unpredictable and outside of the influence and/or
control of the Company.
